| Metric | Value ($ M) | vs Q1 FY26 |
|---|---|---|
| Revenue | 0.34 | 466.7% |
| Total Income | 0.34 | 466.7% |
| Expenditure | 3.04 | 14.8% |
| PBT | — | |
| Net Profit | -2.82 | 17.1% |
| OPM | — | |
| NPM | — | |
| EPS | -0.07 | 12.5% |
Scienture Holdings Reports Q2 2026 Results with Significant Revenue Growth and Improved Operating Performance
21 Aug 2026 · 21 Aug, 1:43 am
Summary
Scienture Holdings, Inc. reported strong Q2 2026 results, with revenue surging approximately 510% sequentially to $343,639. The company achieved a gross margin of approximately 97.7% in Q2 2026 and saw its operating loss improve by 48% year-over-year to $2.7 million. The net loss narrowed by 58% to $2.8 million. Management highlighted these results as an important inflection point, with plans to accelerate top-line revenue growth in the second half of 2026 and into 2027, aiming for profitability in 2027.
Key Highlights
- 1
Revenue increased approximately 510% sequentially to $343,639 in Q2 2026, compared with $56,325 in Q1 2026.
- 2
First-half 2026 revenue increased significantly year-over-year to $399,964, compared with $10,258 for the first six months of 2025.
- 3
Q2 2026 gross margin was approximately 97.7%, compared to $0 in Q2 2025.
- 4
First-half 2026 gross profit increased to $389,629, with a gross margin of approximately 97.4%.
- 5
Q2 2026 operating loss improved approximately 48% year-over-year to about $2.7 million, compared with approximately $5.2 million in Q2 2025.
- 6
Q2 2026 net loss narrowed approximately 58% year-over-year to about $2.8 million, with basic and diluted net loss per share improving to $0.07 from $0.48.
- 7
Commenced the commercial launch of REZENOPY™, establishing the Company’s second commercial product and expanding its revenue-generating portfolio.
Management Comments
Narasimhan Mani
We believe our second-quarter results demonstrate that Scienture has reached an important inflection point. Revenue for Q2 20226 increased about 510% sequentially, from approximately $56,000 in the first quarter to approximately $344,000 in the second quarter. At the same time, we generated gross margins of approximately 98%, reduced operating expenses by about 41% year-over-year and narrowed our net loss by approximately 58%. We also ended the quarter with approximately $11.2 million in cash, cash equivalents and restricted cash, compared with about $6.7 million at year-end 2025, providing us with a stronger financial position as we execute the next phase of our commercial growth strategy. We believe these results demonstrate that we are on the right path to deliver value added business growth in the coming quarters and that we are beginning to realize the operating leverage we have been working toward.
Shankar Hariharan
Arbli’s continued commercial progress gives us confidence in our ability to build and scale differentiated pharmaceutical products, and we believe we have only begun to realize its market opportunity. We are expanding payer access and commercial availability for Arbli™ while simultaneously bringing REZENOPY™ online commercially in the third quarter of 2026. With Arbli™ continuing to gain traction and REZENOPY™ becoming our second commercial-stage product, we believe Scienture is positioned to meaningfully accelerate top-line revenue growth during the second half of 2026 and into 2027. With two differentiated FDA-approved products, approximately 98% gross margins, a strengthened cash position and a more disciplined operating expense structure, we believe we have turned an important corner and established a clear path toward our goal of achieving profitability in 2027.
Informational and educational content only. Not investment advice.